← Every applicant
Jubilant Generics FDA Approvals
13 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| TADALAFILNew drugAug 17, 2026TABLET, ORAL |
| TADALAFILNew drugMay 15, 2026TABLET, ORAL |
| BUMETANIDENew drugAug 5, 2025TABLET, ORAL |
| ESLICARBAZEPINE ACETATENew drugAug 4, 2025TABLET, ORAL |
| PREGABALINNew drugMay 20, 2025CAPSULE, ORAL |
| RANOLAZINENew drugApr 15, 2025TABLET, EXTENDED RELEASE, ORAL |
| DEFERASIROXNew drugApr 11, 2025TABLET, ORAL |
| PERPHENAZINENew drugMar 18, 2025TABLET, ORAL |
| SILDENAFIL CITRATENew drugMar 6, 2025TABLET, ORAL |
| OSELTAMIVIR PHOSPHATENew drugMar 3, 2025FOR SUSPENSION, ORAL |
| SILDENAFIL CITRATENew drugDec 20, 2024TABLET, ORAL |
| LURASIDONE HYDROCHLORIDENew drugDec 6, 2024TABLET, ORAL |
| SOLIFENACIN SUCCINATENew drugOct 2, 2024TABLET, ORAL |